MICROBIAL TECHNOLOGY
Rapid diagnostics – warts and all: a final preview of the BSMT conference
This year’s British Society for Microbial Technology Annual Microbiology Conference will be held on 2 May at the UKHSA, Colindale, North London. Here, BSMT Chair Dr Mark Wilks continues his preview of the meeting focusing on antimicrobial resistance, the UK government’s ambitious programme to control it, and how likely it is to succeed.
‘Contained and controlled: the UK’s 20-year vision for antimicrobial resistance’ is the admirably optimistic title of the government policy paper on solving the problem of antimicrobial resistance (AMR) by the year 2040. The action plan covers action across human and
veterinary medicine, food production, agriculture and research, and focuses on three key ways of tackling AMR: i) reducing need for, and unintentional exposure to, antimicrobials; ii) optimising use of antimicrobials; and iii) investing in innovation, supply and access.
A laudable ambition and it’s hard to
argue against these three key ways, but how are things going so far? The UK’s current five-year National Action Plan (NAP) on tackling AMR, which runs from 2019 to 2024, is coming to an end and as the next five-year NAP is currently being launched, progress made thus far towards the UK’s commitments on AMR is being analysed. It should be pointed out that COVID-19 has had a derailing effect on this programme as in every other aspect of healthcare; indeed, several of our speakers have been seconded to work on different aspects of the COVID-19 outbreak from their normal areas of work. It’s worth looking at the outcomes of a meeting held in November 2022 of UK experts from across the human and animal sectors to discuss their thoughts on progress to date, as well as any recommendations and key considerations they thought should be taken forward.1 Overall, it was agreed that there was a major disparity between the increasing ambitions of the NAP, and the reducing financial support for achieving said ambitions. We will look at how this plays out in the area of STIs later in this article. The gap between evidence generation and implementing recommendations into real-world settings also presents a key challenge to overcome if the NAP’s commitments are to be achieved. A lack of communication and funding
The UK Health Security Agency, Colindale, North London: this year’s venue for the the 39th Annual Microbiology Conference of the British Society for Microbial Technology.
WWW.PATHOLOGYINPRACTICE.COM APRIL 2024
appeared to underpin many of the barriers that prevent the successful delivery of current NAP commitments and were therefore highlighted as key areas of concern for policymakers to consider when looking to tackle AMR. The consensus of the meeting was that the focus should be on successfully implementing and delivering the current NAP commitments rather than identifying future ambitions.
19
UK Health Security Agency / Open Government Licence v3.0
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57
